INNOVAVECTOR SRL

Their core work

INNOVAVECTOR SRL is an Italian biotech SME specializing in the design and production of viral and non-viral gene delivery vectors — the vehicles used to introduce therapeutic genetic material into human cells. Their core contribution to H2020 research was supplying or co-developing vector systems (particularly AAV, adeno-associated virus) for academic gene therapy programs targeting inherited diseases. They sit at the manufacturing and translational end of gene therapy: turning experimental constructs into usable delivery tools that clinical researchers can test in cells, animal models, or early-phase trials. Based in Pozzuoli near Naples, they operate as a specialist service provider embedded in larger EU research consortia rather than as a standalone research group.

What they specialise in

How they've shifted over time

In their earliest H2020 engagement (EYEGET, 2017), INNOVAVECTOR was narrowly focused on AAV-based delivery for a single disease area: inherited retinal degenerations. Their work was essentially disease-specific vector supply for ophthalmology researchers. By 2019 (UPGRADE), the scope shifted markedly toward platform-level precision gene therapy — the same vector expertise applied to hematopoietic stem cells, muscle wasting, and liver diseases, alongside epigenome editing. This suggests the company is moving from single-indication specialist to a multi-indication vector platform provider, following the broader industry trend of applying AAV and non-viral vectors across therapeutic areas rather than optimizing for one disease type.

INNOVAVECTOR appears to be expanding from a niche ophthalmology vector supplier toward a broader gene therapy vector platform company, making them a potentially relevant partner for any research group working on rare genetic diseases in blood, muscle, liver, or eye tissue.

How they like to work

INNOVAVECTOR has participated exclusively as a third party in both of its H2020 projects — meaning they were engaged as a service or resource provider by the main consortium, rather than as a full contractual partner. This is consistent with a specialist manufacturing or vector-supply role: the academic or clinical lead brings them in to provide a defined deliverable (vectors, production batches) without their holding a primary budget line. Their involvement across 11 distinct partners in 6 countries, through only 2 projects, suggests they plug into well-connected consortia as a high-value technical subcontractor rather than building their own scientific network.

Through two projects, INNOVAVECTOR has touched 11 unique consortium partners across 6 countries — a respectable reach for a company of this size and project volume. The network is European in scope, likely anchored to Italian and broader Southern European gene therapy research groups given the Naples-area base.

What sets them apart

INNOVAVECTOR is one of the few Italian private SMEs operating at the intersection of viral vector manufacturing and precision gene editing — a combination that positions them between academic research and clinical translation. Their third-party role in two successive ERC and RIA projects signals that established research teams trust them as a reliable specialist supplier, which is a meaningful signal in the highly regulated gene therapy field. For consortium builders, they offer a way to embed ATMP-adjacent vector expertise into a project without the overhead of a large CRO.

Highlights from their portfolio

• UPGRADE
  A RIA project on unlocking precision gene therapy across multiple disease areas (retina, blood, muscle, liver), UPGRADE shows INNOVAVECTOR's capacity to contribute vector technology at the frontiers of the gene therapy field beyond a single indication.
• EYEGET
  Linked to an ERC Advanced Grant (ERC-ADG funding scheme), EYEGET placed INNOVAVECTOR inside a flagship European research excellence program on inherited retinal disease gene therapy — a strong credibility signal for a small private company.